Keros Therapeutics halts dosing of blood pressure treatment after safety review
Portfolio Pulse from
Keros Therapeutics has voluntarily stopped the use of its 3.0 mg and 4.5 mg doses of a high blood pressure treatment in a mid-stage study due to safety concerns.
December 12, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Keros Therapeutics has paused the dosing of its high blood pressure treatment in a mid-stage study due to safety concerns, which could impact investor confidence and the company's stock price.
The halting of the study due to safety concerns is a significant event for Keros Therapeutics, as it may affect the development timeline and investor confidence. This could lead to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100